Reata Pharmaceuticals reacquires rights from AbbVie to develop and commercialize bardoxolone methyl and omaveloxolone.
Reata Pharmaceuticals, Inc. announced the reacquisition of development, manufacturing and commercialization rights concerning its proprietary Nrf2 activator product platform originally licensed to AbbVie, Inc. for territories outside of the United States with respect to bardoxolone methyl (bardoxolone) and worldwide with respect to omaveloxolone and other next-generation Nrf2 activators.
As a result, Reata now possesses exclusive, worldwide rights to develop, manufacture and commercialize bardoxolone methyl (bardoxolone), omaveloxolone, and all other next-generation Nrf2 activators, excluding certain Asian markets for bardoxolone which are licensed to Kyowa Kirin Co., Ltd. As consideration for the rights reacquired by Reata, AbbVie will receive a total of $330 million in cash, primarily for rights to bardoxolone. Reata will make an upfront payment of $75 million in 2019, with the remainder payable in installments in the second quarter of 2020 and in the fourth quarter of 2021. In addition, AbbVie will receive low single-digit, tiered royalties from worldwide sales of omaveloxolone and certain next-generation Nrf2 activators, and no royalties on bardoxolone.
Reata hit a problem in 2012 when it had to pull the cancel its lead program, bardoxolone, after a data-monitoring committee found that CKD patients in the treatment arm of its phase III study were experiencing a higher rate of heart-related side effects. The ompany cut its staff in half and went back to the drawing board. In 2014 pushed bardoxolone into phase II development in a new indication, pulmonary arterial hypertension (PAH) and started testing another drug, RTA 480, or omavexolone in lung cancer, melanomia and Friedreich�s ataxia. Since then, it has also tested bardoxolone in two types of inherited kidney disease: CKD caused by Alport syndrome and autosomal dominant polycystic kidney disease, a genetic disorder in which numerous cysts grow in the kidneys.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.